Skip to main content

Table 2 Results of immunohistochemistry on MMP-14 in ovarian cancer

From: The role of MMP-14 in ovarian cancer: a systematic review

Author

Tumour samples

Selection of samples

Years

Country

Scoring system

Number of patients or samples

Result MMP-14

Percentage positive

Conclusion

Sakata et al. [56]

Primary tumours

Selection from archive UHa

n.m

Japan

0–5% = 0, 5–50% = 1, > 50% = 2

114

0 benign, 5 borderline, 59 malignant

76%

More MMP-14 expression in tumours with lymphnode metastasis

Torng et al. [64]

Primary tumours, serous and endometroid

Selection from archive UHa

1993–2000

Taiwan

  

positive, numbers n.m.b

 

Expression MMP-14 and MMP-2 correlates

Kamat et al. [57]

Primary tumours

Selection from archive UHa

1990–2000

USA

Overall Score

90

90 epithelial

100, moderate 56%, strong 44%

HRc epithelial MMP-14 2,52 (1.30–4.88)

       

87 stromal

97 (62% low, 38% high)

HRc stromal MMP-14 1,30 (1.03–3.39)

         

Both MMP-14 epithelial and stromal expression correlates with survival

Lin et al. [59]

Primary tumours

Selection from archive UHa

n.m

USA

 

77

 

44% epithelial expression

Strong epithelial MMP-14 expression > 3 risk of death p 0.003

        

40% stromal expression

 

Barbolina et al. [38]

Primary tumours

Selection from archive UHa

n.m

USA

 

149

 

78%, 52% high, 94% in clear cell carcinomas

No relation with stage

Adley et al. [26]d

Primary tumours

Selection from archive UHa

1999–2003

USA

 

143

77

54

32/70 serous, 23/44 endometroid, 5/9 mucinous, 17/18 clear cell

Paulsen et al. [63]

Primary serous borderline tumours and implants

Selection from Cancer Registry (total 632)

1985–1995

Norway

 

Serous borderline tumours

7 moderate, 33 strong/44, 4 weak, 8 moderate, 42 strong/55

 

No difference between group with and without implants, all 7 recurrences positive

Brun et al. [60]

Primary serous and mucinous tumours

Selection from archive UHa

2001–2006

France

HSCORE

Serous

115

benign/borderline 99/95, malignant 134

 
      

Mucinous

44

  

Kato and Motoyama [65]

Primary clear cell and serous carcinomas

Selection from archive UHa

1997–2007

Japan

 

30 clear cell carcinomas

22

73

No relation with stage or survival

      

30 serous carcinomas

1

3

 

Wang et al. [78]

Primary tumours and metastasis

Selection from archive UHa

2001–2006

China

   

positive, numbers n.m.c

Colocalization with uPA, numbers not given

Moss et al. [32]

Primary tumours and metastasis

Selection from archive UHa

n.m.b

USA

0–3

15 serous primary

5 weak, 9 moderate, 1 strong

67

 
      

15 serous metastasis

4 weak, 9 moderate, 2 strong

73

Only 2 metastasis had less expression than the primary tumour

      

2 endometroid

1 weak

50

 
      

2 endometroid metastasis

2 moderate

100

 

Brun et al. [60]

Primary tumours

Consecutive series UHa FIGO III-IV

2001–2006

France

HSCORE

43 primary surgery

132 epithelial/12 stromal

 

No independent prognosticator

      

26 interval surgery

97 epithelial/8 stromal

  

Bruney et al. [49]

Cores of ovarian adenocarcinomas

N.m.b

n.m

USA

 

50

positive, numbers n.m.b

 

Inverse relationship with MUC16/CA 125

Nakayama et al. [74]

Primary tumours

Selection from archive UHa

2005–2011

Japan

 

68

12

18

 

Trudel et al. [79]

Primary tumours

Selection from archive UHa

1993–2006

Canada

Visual score HSCORE

160/170

105

66

No independent prognosticator

Bruney et al. [48]e

Cores of ovarian adenocarcinomas

N.m.b

n.m

USA

 

46

positive, numbers n.m.b

  

Vos et al. [61]

Primary tumours

Consecutive series archives teaching hospital

1997–2003

the Netherlands

Overall Score

94

53 positive epithelial

56

No independent prognosticator

       

49 positive stromal

52

 

Vos et al. [62]

Primary tumours

Consecutive series archives clinical network

2007–2008

the Netherlands

Overall Score

97

52 positive epithelial

54

 
       

5 positive stromal

5

 

Takahashi et al. [80]

Primary tumours

Selection from archive UHa

2000–2014

Japan

Visual and computer-supported evaluation

107 carcinoma's, 54 borderline, 45 benign

positive, numbers n.m.b

 

In-situ proximity assay for EphA2 and MMP-14 positive

Vos et al. [58]

Primary tumours and haematogenic and lymphogenic metastasis

Consecutive series archives teaching hospital

2000–2015

the Netherlands

Overall Score

44

37 primary tumours positive/7 missing

37/44

Most metastasis also positive

       

34 positive stromal/3 negative stromal/7 missing

  
  1. aUH University Hospital
  2. bn.m. Not mentioned
  3. cHR Hazard Ratio
  4. doverlap with study by Barbolina not clear
  5. eoverlap with earlier Bruney study not clear